Menopausal hormone therapy use and breast cancer risk in Australia: Findings from the New South Wales Cancer, Lifestyle and Evaluation of Risk study

International Journal of Cancer

Volumn 138, Issue 8, 2016, Pages 1905-1914

  Salagame, Usha ^a,b   Banks, Emily ^c,d   Sitas, Freddy ^b,e   Canfell, Karen ^a,b,e  

^a CANCER RESEARCH DIVISION   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c The Australian National University   (Australia)

^d SAX INSTITUTE   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Australia; breast cancer; case control study; menopausal hormone therapy

Indexed keywords

ESTROGEN; GESTAGEN; PROGESTERONE; TIBOLONE;

ADULT; AGED; ARTICLE; AUSTRALIA; AUSTRALIAN; BODY MASS; BREAST CANCER; BREAST EXAMINATION; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; FEMALE; HEALTH BEHAVIOR; HIGH RISK PATIENT; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENOPAUSAL HORMONE THERAPY; MENOPAUSAL SYNDROME; MULTICENTER STUDY; OBSERVATIONAL STUDY; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE; REPRODUCTIVE BEHAVIOR; RISK ASSESSMENT; SELF REPORT; TUMOR INVASION; ADVERSE EFFECTS; BREAST NEOPLASMS; CASE CONTROL STUDY; ESTROGEN THERAPY; MIDDLE AGED; NEW SOUTH WALES; ODDS RATIO; RISK FACTOR;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; NEW SOUTH WALES; ODDS RATIO; RISK FACTORS;

EID: 84958875545     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29942     Document Type: Article

References (34)

1. Ferlay J, Soerjomataram I, Ervik M, et al., Globocan 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11[Internet]. Lyon, France: International Agency for Research on Cancer, 2013. Available at: http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx (accessed October 2015).
2. Beral V,; and Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27.
3. Medicines and Healthcare Products Regulatory Agency, UK. Public assessment report: hormone-replacement therapy: safety update (2007). Available at: http://webarchive.nationalarchives.gov.uk/20080527191907/http://mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con2032228.pdf (accessed December 2015).
4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047-59.
5. Salagame U, Canfell K, Banks E., An epidemiological overview of the relationship between hormone replacement therapy and breast cancer. Expert Rev Endocrinol Metab 2011; 6: 397-409.
6. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. IARC Monogr Eval Carcinog Risks Hum 2007; 91: 217-35.
7. IARC Working Group on the Evaluation of Carcinogenic Risks to humans. Pharmaceuticals-a review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012; 100A: 219-82.
8. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy menopausal women: principal results from the Women's Health Initiative randomised controlled trial. JAMA 2002; 288: 321-33.
9. Ravdin PM, Cronin KA, Howlader N, et al., The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007; 356: 1670-74.
10. Kumle M., Declining breast cancer incidence and decreased HRT use. Lancet 2008; 372: 608-10.
11. Canfell K, Banks E, Clements M, et al., Sustained lower rates of HRT prescribing and breast cancer incidence in Australia since 2003. Breast Cancer Res Treat 2009; 117: 671-3.
12. MacLennan AH, Gill TK, Broadbent JL, et al., Continuing decline in hormone therapy use: population trends over 17 years. Climacteric 2009; 12: 122-30.
13. Peng W, Adams J, Hickman L, et al., Complementary/alternative and conventional medicine use amongst menopausal women: results from the Australian Longitudinal Study on Women's Health. Maturitas 2014; 79: 340-2.
14. Gartoulla P, Davis SR, Worsley R, et al., Use of complementary and alternative medicines for menopausal symptoms in Australian women aged 40-65 years. Med J Aust 2015; 203: 146.
15. Sprague BL, Trentham-Dietz A, Cronin KA., A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol 2012; 120: 595-603.
16. Steinkellner AR, Denison SE, Eldridge SL, et al., A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women's Health Initiative. Menopause 2012; 19: 616-21.
17. Sitas F, Yap S, Egger S, et al., The Cancer, Lifestyle and Evaluation of Risk Study (CLEAR): rationale and design of an unmatched "case-spouse control" study of over 10,000 participants in New South Wales, Australia. Cancer Epidemiol 2015; 39: 414-23.
18. Ponsonby AL, Dwyer T, Couper D., Is this finding relevant? Generalisation and epidemiology. Aust N Z J Public Health 1996; 20: 54-6.
19. Colditz GA., Epidemiology of breast cancer. Findings from the nurses' health study. Cancer 1993; 71: 1480-9.
20. Kelsey JL, Bernstein L., Epidemiology and prevention of breast cancer. Annu Rev Public Health 1996; 17: 47-67.
21. Velie EM, Nechuta S, Osuch JR., Lifetime reproductive and anthropometric risk factors for breast cancer in postmenopausal women. Breast Dis 2005; 24: 17-35.
22. Gertig DM, Fletcher AS, English DR, et al., Hormone therapy and breast cancer: what factors modify the association? Menopause 2006; 13: 178-84.
23. Anderson GL, Chlebowski RT, Aragaki AK, et al., Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012; 13: 476-86.
24. Manson JE, Chlebowski RT, Stefanick ML, et al., Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013; 310: 1353-68.
25. Chlebowski RT, Rohan TE, Manson JE, et al., Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 women's health initiative randomized clinical trials. JAMA Oncol 2015; 1: 296-305.
26. Prentice RL, Chlebowski RT, Stefanick ML, et al., Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol 2008; 167: 1407-15.
27. Joffe MM, Byrne C, Colditz GA., Postmenopausal hormone use, screening, and breast cancer: characterization and control of a bias. Epidemiology 2001; 12: 429-38.
28. Ewertz M, Mellemkjaer L, Poulsen AH, et al., Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer 2005; 92: 1293-7.
29. Australian Statistics on Medicine Reports. Available at: http://www.pbs.gov.au/info/browse/statistics (accessed September 2015).
30. Prentice RL, Chlebowski RT, Stefanick ML, et al., Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2008; 167: 1207-16.
31. WHO Global Database on Body Mass Index. Accessed at: http://apps.who.int/bmi/index.jsp (accessed September 2015).
32. Canfell K, Banks E, Moa AM, et al., Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 2008; 188: 641-4.
33. Chlebowski RT, Kuller LH, Prentice RL, et al., Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009; 360: 573-87.
34. Marshall SF, Clarke CA, Deapen D, et al., Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort. Breast Cancer Res 2010; 12: R4.